Current Report Filing (8-k)
November 01 2018 - 4:08PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date
of earliest event reported): October 31, 2018
STAAR
Surgical Company
(Exact Name of Registrant
as Specified in Charter)
Delaware
|
0-11634
|
95-3797439
|
(State or Other Jurisdiction
|
(Commission
|
(I.R.S. Employer
|
of Incorporation)
|
File Number)
|
Identification No.)
|
|
|
|
1911 Walker Ave., Monrovia, California
|
91016
|
(Address of Principal Executive Offices)
|
(Zip
Code)
|
Registrant’s Telephone Number, Including
Area Code
626-303-7902
Not Applicable
(Former Name or Former Address, if Changed Since
Last Report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (
see
General Instruction A.2. below):
|
¨
|
Written
communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement
communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement
communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1 933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange
Act of 1934 (17 CFR §240.12b-2).
Emerging
growth company
¨
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01 Regulation FD Disclosure.
On October 31, 2018, the Company held a
conference call to discuss the financial results for the quarter ended September 28, 2018. A transcript of the conference call
is furnished as Exhibit 99.1 to this report and is incorporated herein by this reference.
The information furnished herewith pursuant
to Item 7.01 of this Current Report, including Exhibit 99.1, shall not be deemed to be “filed” for the purposes of
Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities
of that section. The information in Item 7.01 of this Current Report shall not be incorporated by reference into any filing under
the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date of this Current Report, regardless
of any general incorporation language in the filing.
Item 9.01 Financial Statements and Exhibits
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
STAAR Surgical Company
|
|
November 1, 2018
|
By:
|
/s/ Caren Mason
|
|
|
Caren Mason
|
|
|
President and Chief Executive Officer
|
STAAR Surgical (NASDAQ:STAA)
Historical Stock Chart
From Aug 2024 to Sep 2024
STAAR Surgical (NASDAQ:STAA)
Historical Stock Chart
From Sep 2023 to Sep 2024